Document Detail


Secondary myelodysplastic syndrome in a patient with Philadelphia-positive acute lymphoblastic leukemia after achieving a major molecular response with hyperCVAD plus imatinib mesylate.
MedLine Citation:
PMID:  18355919     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
The addition of imatinib to high-intensity chemotherapy has improved the outcome of patients with Philadelphia chromosome (Ph)-positive acute lymphoblastic leukemia (ALL). However, the possible long-term side effects of this combination are not yet known. Development of new clonal abnormalities in complete cytogenetic remission after treatment with imatinib has been reported in patients with chronic myeloid leukemia but not in patients with Ph-positive ALL. Here, we present a patient with Ph-positive ALL who received hyperCVAD plus imatinib and achieved hematologic, cytogenetic, and major molecular responses. The patient then developed myelodysplastic syndrome and solitary central nervous system relapse of ALL.
Authors:
Arturo Vega-Ruiz; Susan O'Brien; Jorge Cortes; Partow Kebriaei; Deborah Thomas; Hagop Kantarjian; Farhad Ravandi
Related Documents :
3166449 - Prediction of impending blast cell transformation in chronic granulocytic leukaemia.
18061959 - A correlation study of immunophenotypic, cytogenetic, and clinical features of 180 aml ...
3470169 - Iatrogenic myelomonocytic leukemia following melphalan treatment of scleromyxedema.
3617109 - Small-dose cytosine arabinoside in the treatment of elderly patients with acute leukemi...
272799 - Rapid cytoreduction in acute leukemia. management of cerebral leukostasis by cell phere...
3475159 - Sequential karyotype study on ph-positive chronic myelocytic leukemia. significance of ...
1573949 - Ultrasonography for the diagnosis of lyme disease in cases of acute facial paralysis.
16596379 - Increased 67gallium uptake among polymyalgia rheumatica patients. is it additional evid...
18556379 - Impact of early nephrology referral on mortality and hospitalization in peritoneal dial...
Publication Detail:
Type:  Case Reports; Journal Article     Date:  2008-03-19
Journal Detail:
Title:  Leukemia research     Volume:  32     ISSN:  0145-2126     ISO Abbreviation:  Leuk. Res.     Publication Date:  2008 Sep 
Date Detail:
Created Date:  2008-05-16     Completed Date:  2008-07-24     Revised Date:  2014-09-04    
Medline Journal Info:
Nlm Unique ID:  7706787     Medline TA:  Leuk Res     Country:  England    
Other Details:
Languages:  eng     Pagination:  1468-71     Citation Subset:  IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Antineoplastic Agents / therapeutic use*
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
Benzamides
Central Nervous System Neoplasms / etiology*,  pathology
Cyclophosphamide / therapeutic use
Cytogenetic Analysis
Dexamethasone / therapeutic use
Doxorubicin / therapeutic use
Female
Hematopoietic Stem Cell Transplantation
Humans
Leukemia, Myelogenous, Chronic, BCR-ABL Positive / etiology,  pathology,  therapy
Middle Aged
Myelodysplastic Syndromes / etiology*,  pathology,  therapy
Neoplasms, Second Primary / etiology*,  pathology,  therapy
Piperazines / therapeutic use*
Precursor Cell Lymphoblastic Leukemia-Lymphoma / complications,  drug therapy*
Protein-Tyrosine Kinases / antagonists & inhibitors
Pyrimidines / therapeutic use*
Remission Induction
Treatment Outcome
Vincristine / therapeutic use
Grant Support
ID/Acronym/Agency:
P30 CA016672/CA/NCI NIH HHS
Chemical
Reg. No./Substance:
0/Antineoplastic Agents; 0/Benzamides; 0/Piperazines; 0/Pyrimidines; 57-22-7/Vincristine; 7S5I7G3JQL/Dexamethasone; 80168379AG/Doxorubicin; 8N3DW7272P/Cyclophosphamide; BKJ8M8G5HI/imatinib; EC 2.7.10.1/Protein-Tyrosine Kinases
Comments/Corrections

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Tel/PDGFRbeta inhibits self-renewal and directs myelomonocytic differentiation of ES cells.
Next Document:  Intraocular concentration of triamcinolone acetonide after intravitreal injection in the rabbit eye.